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Abstract 
Introduction: It is challenging at baseline to predict when and which individuals who meet criteria for 
mild cognitive impairment (MCI) will ultimately progress to Alzheimer’s disease (AD) dementia.  
Methods: A deep learning method is developed and validated based on MRI scans of 2146 subjects 
(803 for training and 1343 for validation) to predict MCI subjects’ progression to AD dementia in a time-
to-event analysis setting.  
Results: The deep learning time-to-event model predicted individual subjects’ progression to AD 
dementia with a concordance index (C-index) of 0.762 on 439 ADNI testing MCI subjects with follow-up 
duration from 6 to 78 months (quartiles: [24, 42, 54]) and a C-index of 0.781 on 40 AIBL testing MCI 
subjects with follow-up duration from 18-54 months (quartiles: [18, 36,54]). The predicted progression 
risk also clustered individual subjects into subgroups with significant differences in their progression time 
to AD dementia (p<0.0002). Improved performance for predicting progression to AD dementia (C-
index=0.864) was obtained when the deep learning based progression risk was combined with baseline 
clinical measures.  
Conclusion: Our method provides a cost effective and accurate means for prognosis and potentially to 
facilitate enrollment in clinical trials with individuals likely to progress within a specific temporal period. 
Keywords: deep learning; hippocampus; time-to-event analysis; Alzheimer’s disease   
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Background  
Individuals with mild cognitive impairment (MCI) are at a higher risk to develop dementia (usually due to 
Alzheimer’s Disease (AD)), with an annual progression rate up to 10~20% [1]. Although clinical criteria 
for MCI and AD have been developed to formalize assessment of the gradual progression of the disease, 
it remains difficult at baseline to predict when and which individuals who meet criteria for MCI will 
ultimately progress to AD dementia.  
The early prediction of AD dementia has been typically modeled as a pattern classification 
problem. For instance, by dichotomizing MCI subjects into progressive MCIs (pMCIs) and stable MCIs 
(sMCIs) based on a cut-off threshold of follow-up duration, a binary classifier is then trained based on 
baseline data to distinguish pMCIs from sMCIs. To early predict AD dementia based on neuroimaging 
data, machine learning techniques have been adopted to build classifiers upon imaging data, and 
prominent brain structural differences have been identified between AD and cognitively normal (NC) 
subjects as well as between pMCI and sMCI subjects within the medial temporal lobe (MTL), including 
regions such as hippocampus and entorhinal cortex [2-11]. The existing classification studies typically 
adopt relatively simple imaging measures, such as brain tissue density, volume, cortical thickness, and 
geometric characteristics of hippocampus. These hand-crafted measures might be less discriminative for 
the AD prognosis. For predicting MCI subjects’ progression to AD dementia it is a suboptimal strategy to 
distinguish pMCI from sMCI subjects in a classification setting in that the classification performance is 
hindered on the cut-off threshold of follow-up duration to define pMCI and sMCI, and the cohorts of pMCI 
and sMCI subjects are highly heterogeneous regardless of the threshold used. More importantly, the 
classification based early prediction of AD dementia does not provide specific information about the timing 
of when MCI patients cross the threshold to AD dementia. 
Recent studies have moved the focus onto the prediction of timing of progression to AD over the 
follow-up duration using time-to-event analysis techniques [12-16]. Clinical and imaging based measures 
at baseline and their longitudinal change trajectory have been adopted for predicting MCI subjects’ 
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progression to AD dementia, and promising performance have been achieved. However, only simple 
imaging features or individual clinical measures have been investigated, which might be less 
discriminative for the prognosis. 
To better predict individual MCI subjects’ progression to AD dementia based on baseline structural 
MRI data, we develop a deep learning framework to extract informative features from hippocampal MRI 
data, and build a prognostic model upon the extracted features to predict progression of MCI subjects in 
a time-to-event analysis setting. We have evaluated the proposed method using baseline structural MRI 
data of subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) [17-19] (including ADNI-1, 
ADNI-GO&2), and the Australian Imaging Biomarkers and Lifestyle Study of Aging (AIBL) [20]. We also 
compared the deep learning based imaging features with conventionally hand-crafted imaging features. 
Methods 
Imaging and clinical data 
We included data from the ADNI (http://adni.loni.usc.edu) and AIBL (www.aibl.csiro.au) cohorts, 
consisting of baseline MRI scans of 1711 ADNI subjects and 435 AIBL subjects. The data were 
downloaded on April 05, 2017. For up-to-date information, see www.adni-info.org. 
We used MRI data (n=803 scans) from the ADNI-1 to train the proposed prognostic model. Then 
we validated the proposed model with independent data from the ADNI-GO&2 and the AIBL. For the 
ADNI-GO cohort only new add-on subjects (no overlap with ADNI-1) were used for the validation. The 
present study included all MCI subjects with baseline MRI scans and at least one clinical follow-up data 
point, including those who converted back from MCI to Normal Cognition. The characteristics of the 
cohorts included in this study are summarized in tables S1, S2, and S3 of supplementary material. In the 
present study, the ADNI-1 scans were collected using 1.5T scanners, the ADNI-GO&2 scans were 
collected using 3T scanners, and the AIBL scans were collected using 3T scanners.  
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Clinical variables include age, sex, education, APOE4 (Apolipoprotein E4), the 13-item version of 
the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog13), Rey Auditory Verbal 
Learning Test (RAVLT) immediate, RAVLT learning, Functional Assessment Questionnaire (FAQ), and 
Mini-Mental State Examination (MMSE), were obtained for MCI subjects from the ADNI cohorts. 
Particularly, the ADAS-Cog13 consists of 11-item (word recall, commands, constructional praxis, naming, 
ideational praxis, orientation, word recognition, remembering test instructions, comprehension, word 
finding difficulty, spoken language ability) ADAS-cog plus 2 additional items (delayed word recall and 
number cancellation). 
We also analyzed MCI subjects of the ADNI-GO&2 cohorts in terms of their amyloid positive status. 
Particularly, amyloid positive subjects were defined as those with a CSF (cerebrospinal fluid) Aβ42 
(amyloid beta peptide 42) level below 192 pg/mL or with a summary AV-45 (Florbetapir-F18) cortical 
standardized uptake value ratio (SUVR) normalized by the whole cerebellum above 1.11 when CSF Aβ42 
level was not available. 
Hippocampus extraction 
T1 MRI scans were registered to the MNI space using affine registration and resampled at a spatial 
resolution of 1 × 1 × 1 mm3. Bilateral hippocampal regions were segmented from the T1 images for each 
subject using the local label learning (LLL) [21] algorithm with 100 hippocampus atlases obtained from a 
preliminary release of the EADC-ADNI harmonized segmentation protocol project (www.hippocampal-
protocol.net) [22]. A 3D bounding box of size 29 × 21 × 55 was then adopted to extract hippocampus 
regions from the T1 images using the segmentation labels. These hippocampal data were used to extract 
features and build the prognostic models. 
Deep learning for informative feature extraction 
A deep learning model of convolutional neural networks (CNNs) with residual connections was trained to 
learning informative features for distinguishing AD from NC subjects. As illustrated in Fig. 1B, the left and 
right hippocampal images were inputs to the deep learning model with two streams, each for one 
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hippocampus. Each stream of the deep learning model consisted of 1 convolutional layer (Conv), followed 
by 3 residual blocks (ResBlocks) [23], and 1 global average pooling (GAP) layer [24]. As illustrated in Fig. 
1C, each of the ResBlocks had 2 Conv layers with a direct connection between its input and output. 
These two streams’ outputs were then flattened and concatenated as input to a fully connected layer (FC) 
for building the classification model. Rectified linear units (ReLUs) were used as nonlinear activation 
functions and max pooling layers were adopted to learn features at multiple scales. Batch normalization 
(BN) was adopted in our deep learning model [25], and the GAP layers facilitated visualization of the 
learned features through AD-like relevance maps [24]. Specifically, each of the Conv layers contained 32 
kernels, the ResBlocks 1, 2, and 3 contained 32, 64, and 128 kernels respectively, and all these kernels 
had the same size of 3 × 3 × 3. The max pooling layer had a stride of 2 × 2 × 2 and a kernel size of 2 ×
2 × 2. Outputs of the GAP layers were concatenated and followed by a dropout operation with a ratio of 
0.5 to form an input vector for the FC to make the diagnosis of the input data. Once the deep classification 
model was obtained, new image could be fed into the deep learning model and its deep learning features 
(1 × 256 feature vector in this study) were extracted as the output of the GAP layers and used as the 
input to time-to-event prognostic models.  
Time-to-event prognostic model based on deep imaging features 
Based on the deep learning features, a prognostic model for predicting individual subject’s timing of 
progression to AD dementia was built using LASSO regularized Cox regression model [26]. Particularly, 
the prognostic model was trained based on the ADNI-1 cohort, and its prognostic performance was 
evaluated based on the ADNI-GO&2 and AIBL cohorts. The overall training and validation procedures 
are illustrated in Fig. 1A. The LASSO model’s regularization parameter was optimized using 10-fold 
cross-validation based on the training data. The time-to-event prognostic model estimates overall risk 
scores to progress to AD dementia for individuals. Individuals with higher risk scores will progress to AD 
sooner than those with lower risk scores. An annual probability value of progression to AD can be 
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estimated based on the risk score, given a baseline hazard (progression to AD) function, which could be 
estimated based on training cohort [27]. 
 
A 
  
B C 
Fig. 1. Schematic illustration of the deep learning based AD prognosis. (A) A general flowchart for training 
and validating the prognostic model. (B) Deep network architecture for data-driven hippocampus-based 
AD diagnosis. (C) residual block. L: left hippocampus; R: right hippocampus. (NC: cognitively normal 
control; AD: Alzheimer’s disease; MCI: mild cognitive impairment; Conv: convolutional layer; BN: batch 
normalization; ReLU: rectified linear unit; ResBlock: residual block; Concat: concatenation layer; FC: fully 
connected layer). 
 
Time-to-event prognostic model when deep imaging features meet clinical variables 
Based on the deep learning prognostic model, risk of progression to AD could be estimated for each MCI 
subject. The estimated risk was combined with clinical variables including age, sex, education, APOE4, 
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ADAS-Cog13, RAVLT immediate, RAVLT learning, FAQ, and MMSE to build a second prognostic model 
using Cox regression [28]. The prognostic model was trained based on the ADNI-1 MCI subjects and 
evaluated based on the ADNI-GO&2 data. Since the AIBL did not provide all these clinical measures, we 
did not evaluate the prognostic model based on the AIBL data.  
To evaluate significance of the deep learning features when combined with the clinical measures 
for the prediction of AD dementia, we had also built another prognostic model of MCI subjects based on 
the AD score (probability) estimated by the deep AD/NC classification model and baseline clinical 
variables using Cox regression. The prognostic model was also trained on the ADNI-1 data and evaluated 
on the ADNI-GO&2 data.  
Validation and comparisons 
We evaluated the proposed method and compared it with state-of-the-art alternative image feature 
extraction methods [29] based on the same training and validation datasets. All the models were trained 
using the ADNI-1 data, and validated using the ADNI-GO&2 and AIBL data. We compared the deep 
learning models with those built on conventional hippocampal imaging features, including shape features 
and texture features (Details in supplementary material). Particularly, two alternative models were built 
on shape features only and a combination of shape and texture features (denoted as shape & texture 
thereafter) respectively. 
In order to directly access reproducibility of our deep learning features across scanners with 
different magnetic field strengths, we obtained 1.5T and 3T scans of the same subjects of the ADNI-1 
cohort (n=113, 37 NC, 50 MCI, and 26 AD), computed their deep learning features, and finally measured 
comparability between deep learning features of 1.5T and 3T scans and between their predicted risk 
scores for individual subjects. 
 In order to evaluate the deep imaging features’ discriminative power, we compared its 
performance for distinguishing AD from NC subjects with alternative classification models based on 
conventional hippocampal shape and texture features. Random forests (RF) [30] were adopted to build 
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classification models upon the conventional features (Details in supplementary material). Classification 
accuracy, receiver operating characteristic (ROC) curve, and area under ROC curve (AUC) were used to 
evaluate all the models under comparison. We adopted Delong test to compare AUC measures obtained 
by different models.  
 In order to investigate how different parts of the hippocampal imaging data contributed to the 
classification, class relevance maps [24] with respect to AD were obtained for all the subjects from the 
validation cohorts, and mean relevance maps of different subject groups including NC, sMCI, pMCI, and 
AD were obtained respectively. MCI subjects who progressed to AD from 0.5 to 3 years from the baseline 
scan were defined as pMCI (mean/standard deviation: 1.69/0.93 years, quartiles: [1, 2, 2.5] years), 
otherwise defined as sMCI for this visualization analysis. It is worth noting that we do not need to define 
pMCI and sMCI for the time-to-event analyses. 
 We further investigated the associations between the deep hippocampal imaging features and 
clinical measures including MMSE, ADAS-cog13, RAVLT immediate, RAVLT learning, FAQ, A𝛽 status 
(positive or negative), and APOE4, Pearson’s correlation coefficients were adopted to measure the 
potential associations.  
 In order to evaluate the performance of prognostic models built on different kinds of imaging 
features, concordance index (C-index) and time-dependent ROC curves were adopted to evaluate their 
accuracy. Particularly, the C-index measures proportion of all possible pairs of subjects, at least one of 
whom has progressed to AD dementia, in which the predicted progression risk (probability) is larger for 
the subjects who progressed to AD dementia in a shorter time [31], while the time-dependent ROC curves 
access prediction performance of progression of AD dementia at different observed times [32]. The time-
dependent ROC curves were adopted so that the performance of prognostic models could be evaluated 
using ROC curves that are widely used to illustrate sensitivity and specificity of a continuous diagnostic 
marker for predicting a binary clinical outcome variable in classification studies. Since the status of 
progression of AD is dependent on the follow-up time, binary status of progression of AD could be 
obtained at different cut-off time points to compute their corresponding ROC curves, yielding time-
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dependent ROC curves [33]. A nonparametric approach [34] was adopted to estimate and compare C-
index values, and nonparametric inverse probability of censoring weighting estimators  [32] were adopted 
to obtain and compare time-dependent ROC based measures. The prognostic accuracy was also 
evaluated for amyloid positive MCI subjects alone. All the measures were calculated in R.  
We investigated the subject stratification results based on the prognostic risks of progression to 
AD dementia for MCI subjects. Specifically, all the MCI subjects were categorized into 3 sub-groups with 
low, middle, and high predicted risks of progression to AD dementia, and Kaplan-Meier plot was adopted 
to investigate their progression to AD dementia based on real follow-up duration information. 
Results 
Mean of correlations between the deep learning features of 1.5T and 3T scans of the 113 ADNI-1 subjects 
was 0.955±0.023 (quantiles: [0.930, 0.958, 0.979]), and mean of intra-class correlation coefficients (ICCs) 
across all the deep learning features was 0.950±0.026 (quantiles: [0.925, 0.951, 0.978]), demonstrating 
that the deep learning features were robust to magnetic field strength differences. The ICC between the 
predicted risk scores of the 1.5T and 3T scans was 0.982, demonstrating that the prediction performance 
was also robust to the differences in magnetic field strength.  
The deep learning classifier’s accuracy rates for distinguishing AD from NC subjects on the ADNI-
GO&2 and AIBL cohorts were 0.900 and 0.929 respectively, and AUC values were 0.956 and 0.958 
respectively. Delong test indicated that the deep learning classifier performed significantly better than the 
RF based classifiers in terms of their AUC measures (p<0.008). Fig. S2 (supplementary material) shows 
ROC curves of the classifiers under comparison. 
Fig. 2 illustrates the mean AD-like relevance maps for NC, sMCI, pMCI, and AD groups of the 
ADNI-GO&2 cohorts. We found that the relevance map of the AD subjects highlighted both the anterior 
and posterior hippocampus, the pMCI subjects’ highlighted the anterior hippocampus, and maps of the 
NC and sMCI subjects had relatively weak relevance.  
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Fig. 2. Mean AD-like relevance maps for different subject groups, demonstrating the discriminative sub-
regions that distinguish AD from NC and characterizing the imaging patterns along the pathological 
progression of AD. Warmer color indicates severer brain degeneration and more relevant to the 
progression to AD and cool color indicates rare brain degeneration and irrelevant to the progression to 
AD. The hippocampus panel shows mean hippocampal segmentation maps across subjects in different 
views (A: anterior, P: posterior, M: medial, L: lateral, S: superior, I: inferior). The mean maps have values 
in [0,1], indicating each voxel’s percentage for being located in the hippocampus across subjects whose 
brain images were registered to the MNI space. The segmentation maps serve as spatial references to 
the hippocampal locations for the AD relevance maps. NC: cognitively normal control; AD: Alzheimer’s 
disease; MCI: mild cognitive impairment; sMCI: stable MCI; pMCI: progressive MCI. 
 
 Fig. 3 shows that the correlation coefficients between top 50 deep learning features with largest 
weights in the deep learning classifier and cognitive measures and biomarkers across all subjects of the 
ADNI-GO&2 cohorts, indicating that the deep learning features were significantly correlated with clinical 
measures (Pearson’s correlation, p<0.05). Fig. S3 (supplementary material) shows that  amyloid negative 
MCI subjects had significantly lower progression risks compared with amyloid positive subjects (p<6.0 ×
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10−13, Wilcoxon rank sum tests). These results demonstrated that the deep imaging features were 
informative to capture the characteristics of AD related biomarkers and cognitive measures.  
 
Cognitive measures, A𝜷 status, and APOE4 status 
 
Fig. 3. Top 50 features with largest weights in the deep classification model for AD/NC diagnosis were 
significantly correlated to cognitive/biological measures across all the subjects of the ADNI-GO&2 
cohorts. The box plots show median/quartiles of correlation coefficients between pairs of one 
cognitive/biological measure and each of top 50 deep learning features. The outliers are plotted using 
the ‘+’ symbol. (MMSE: Mini–Mental State Examination; ADAS-cog13: 13-item version of the Alzheimer’s 
Disease Assessment Scale-Cognitive subscale; RAVLT: Rey Auditory Verbal Learning Test; FAQ: 
Functional Assessment Questionnaire; Aβ: amyloid beta peptide 42; APOE4: Apolipoprotein E4). 
 
 The prediction accuracy of the prognostic models built upon hippocampal imaging features are 
summarized in Table 1. The deep learning model predicted the ADNI-GO&2 MCI subjects’ progression 
to AD dementia with a C-index of 0.762, significantly better than those built upon conventional shape and 
texture image features (p<0.03 [34]). The deep leaning model predicted the AIBL MCI subjects’ 
progression to AD dementia with a C-index of 0.781, better than those built upon conventional shape 
(p=0.037). However, the difference between prediction models built on the deep learning imaging 
features and the shape & texture image features was not statistically significant (p=0.694 [34]). As shown 
in Fig.4 (top row), the AUC measures of time-dependent ROC curves obtained by the deep learning 
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based model on follow-up durations from year 1 to year 3 were 0.75, 0.778, and 0.813 respectively on 
the ADNI-GO&2 cohorts, better than the alternative models (the differences were significant when 
compared with prediction models built on the shape features at year 2, and on both the shape and shape 
& texture features at year 3, p<0.04 [32]).  
Table 1. Prediction performance of prognostic models built upon different types of features. 
            C-index 
 
Cohort 
Hippocampal imaging features 
Clinical 
measures 
Clinical measures with 
deep learning imaging 
features Shape 
Shape & 
Texture 
Deep learning 
ADNI GO&2 
0.676 
(0.0006) 
0.707 (0.024) 0.762 0.848 (0.05) 0.864 
AIBL 0.655 (0.037) 0.762 (0.694) 0.781   
𝑝 values between deep learning based model and alternatives are demonstrated in the parenthesis. 
The clinical measures included APOE4 status, all cognitive measures, and demographic data. 
 
 
 
 
Fig. 4. Time-dependent ROC curves of prognostic models built upon different imaging features at follow-
up durations from year 1 to year 3 on the ADNI-GO&2 cohorts. Top row: all the ADNI-GO&2 MCI subjects; 
Bottom row: Amyloid positive MCI subjects of the ADNI-GO&2 cohorts.  
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The prediction model built on the deep learning imaging features predicted the amyloid positive 
subjects’ progression to AD with a C-index of 0.733, better than those built on the conventional shape 
and shape & texture imaging features (with C-index of 0.656 and 0.680 respectively, p=0.004 and 0.06 
[34]). As shown in Fig.4 (bottom row), the AUC measures of time-dependent ROC curves obtained by 
the deep imaging feature based model at follow-up durations from year 1 to year 3 were 0.731, 0.762, 
and 0.789 respectively, better than the alternative models (the differences were significant when 
compared with prediction models built on the shape features at year 2 and 3, p<0.05 [32]). The deep 
learning feature based model also performed better than prediction models built upon hippocampal 
volumes (supplementary material). 
The predicted progression risk to AD dementia also clustered MCI subjects from ADNI-GO&2 into 
subgroups with significant differences in their timing of progression (p<0.0002, Log-rank test) with age, 
sex, education and APOE4 status as covariates, as demonstrated by the Kaplan-Meier plots in Fig. 5. 
 
Fig. 5. Kaplan-Meier plots of MCI subgroups with different progression risks in terms of conversion to 
AD estimated by the deep learning prediction model on testing MCI subjects of the ADNI-GO&2 cohorts 
(Low: the 1st quartile, High: the 4th quartile, Middle: 2nd and 3rd quartiles). The subgroups were 
significantly different in their conversion timing to AD (Log-rank test, p<0.0002). 
 The prediction model built upon the predicted AD dementia progression risks (based on deep 
learning features) and baseline clinical measures achieved improved performance (C-index=0.864) on 
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the ADNI-GO&2 cohorts, significantly better than the model built on clinical measures alone (C-
index=0.848, p=0.05). As summarized in Table S4 and S5, RAVLT_immediate, FAQ, and the deep 
learning features were top 3 predictors for predicting progression to AD dementia (p<1 × 10−5). We have 
further estimated performance of prediction models built on different combinations of imaging features, 
Aβ measures, APOE4 status, and cognition measures, in addition to demographic data (age, sex, and 
education). As summarized in Tables S6 and S7 (supplementary material), the combination of the deep 
learning imaging features and demographic measures had significantly better prediction performance 
than the combination of MMSE and demographic measures (p=0.0004). Among the cognitive measures, 
ADAS-cog13 had the best prediction performance when combined with demographic measures, and the 
difference in terms of prediction performance between the deep learning imaging features and the ADAS-
Cog13 was not statistically significant when combined with the demographic data (p=0.257). The deep 
learning imaging features had similar performance as A𝛽 and APOE4 measures when combined with all 
the cognitive measures.  
Discussion 
In this study, we proposed a deep learning framework for early prognosis of AD dementia based on the 
hippocampal MRI data. We trained a deep learning classifier based on the ADNI-1 cohort for extracting 
informative imaging features, and built a time-to-event prognostic model on these features to predict the 
progression to AD dementia for MCI subjects of the ADNI-GO&2 and AIBL cohorts. We demonstrated 
that the deep learning prediction model could achieve promising performance for predicting MCI subjects’ 
progression to AD dementia and identifying subgroups of subjects with different progression patterns.  
 Deep learning techniques have been explored for the prognosis of AD dementia [35-38]. These 
studies adopted a classification setting to predict MCI progression, and had to dichotomize the training 
data into progressive or stable MCIs based on certain cut-off threshold. Therefore, their prediction 
performance was dependent on their cut-off thresholds. Instead of formulating the early prediction of MCI 
subjects’ progression to AD dementia as a binary classification problem, we built a prognostic model 
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under a time-to-event analysis setting. The time-to-event prognostic model took into consideration the 
timing of progression to AD dementia, and could estimate the timing/risk of progression to AD dementia 
for each individual subject, which could be used to monitor their disease progression longitudinally. Our 
prediction results could also be analyzed using the conventional ROC curves, i.e., the time dependent 
ROC curves. On the other hand, the estimated risk could also facilitate stratification of MCI subjects to 
identify those with higher risk to progress to AD dementia as demonstrated in Fig. 5. 
A very striking finding in our study was the clear advantage of the use of deep learning 
hippocampal features in predicting progression to dementia compared with the hippocampal volume, 
which is frequently used in the literatures as a marker of neurodegeneration [39]. Maybe due to 
practicality in assessment, most of the attention has been given so far for the volumetric features of the 
hippocampus rather than other features in exploring dementia. However, even in structural MRI the 
dementia related changes in the hippocampus seem to be better exploited with the deep learning features 
we are proposing for more robust progression prediction.  
Several studies have specifically focused on the hippocampus for early diagnosis of AD and built 
predictive models upon anatomical features such as the hippocampal volume and shape based 
measures and image intensity texture features [5, 6, 40-44]. Although promising performance of the 
hippocampus shape features [45-47], texture features [48] and CNNs based features [43, 49] has been 
demonstrated for the classification of AD patients, their classification setting ignored the timing of 
progression to AD dementia. Moreover, it is challenging to define the pMCI and sMCI under a 
classification setting due to high heterogeneity of the AD continuum. Several recent studies [12-15] have 
focused on the prediction of time of progression to AD dementia under a time-to-event analysis setting; 
however, relatively simple features, e.g., volumetric and geometric measures, were included in the 
prognostic analysis. The discriminative power of these hand-crafted measures are relatively limited, 
especially when used for more complex prognostic tasks. As demonstrated in Fig. S2, the deep imaging 
features performed significantly better than conventional shape and texture features for distinguishing 
AD from NC subjects on both the ADNI-GO&2 and AIBL cohorts, indicating that the deep imaging features 
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are more discriminative, and may have better potentials for characterizing the hippocampal changes 
related to AD dementia. It also demonstrated good generalization performance across different cohorts. 
Sub-regions of the hippocampus, as shown in Fig. 2, contributed differently to characterize the 
AD related differences. The relevance map of the AD subjects highlighted both the anterior and posterior 
hippocampus, the pMCI subjects’ map highlighted the anterior hippocampus, and maps of the NC and 
sMCI subjects had relatively weak relevance. These results were largely consistent with patterns of MCI 
and AD subjects described in existing studies [50, 51]. It also suggested that the anterior hippocampus 
was involved along the progression to AD prior to the posterior part [52, 53]. These relevance patterns 
have demonstrated that the deep features were indeed extracted from the AD related hippocampus 
regions. As the CNNs was optimized to learn discriminative imaging features, representing an evolution 
of imaging features from low-level intensity contrast to high-level complex patterns, for better 
differentiating AD from NC, it is speculated that the learned imaging features might reflect the AD relevant 
microstructural alternations in the hippocampal regions, and different weights of sub-regions 
demonstrated their involvement in these changes. These imaging alternations might be results of 
pathophysiological changes such as neuronal loss [54]. 
 As shown in Fig. 3, we also found that the deep learning features were significantly correlated 
with cognitive measures and AD related biomarkers. Moreover, we found that amyloid positive MCIs who 
have molecular evidence of prodromal AD had higher predicted AD dementia progression risks than 
amyloid negative MCIs [55]. 
  Different quantitative evaluation measures, as shown in Table 1 and Fig. 4, have demonstrated 
that the deep imaging features’ superiority for predicting the MCI subjects’ progression to AD on different 
cohorts, compared with the conventional shape and texture features. The deep learning prediction model 
also performed significantly better than other prediction models built upon conventional imaging features 
for amyloid positive subjects. Fig. 4 shows that the AUC values of the A𝛽 positive MCI subjects were 
smaller than those of all MCI subjects. This difference in AUC values was a result of the difference in the 
testing data sets, and the risk scores of individual A𝛽 positive MCI subjects were the same regardless of 
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the computation of AUC values. Comparisons in terms of AUC values should be based on the same data 
set since the AUC values are summary measures for certain testing data sets. Nonetheless, it is possible 
that measures of neurodegeneration in the hippocampus would have better predictive power than 
amyloid status alone, as the former measure is more tightly linked to disease progression. 
The prognostic performance of the prognostic model built on the combination of deep learning 
imaging features and clinical measures worked significantly better than that built on clinical measures 
alone. Particularly, RAVLT_immediate, FAQ, and the deep learning imaging features were top 3 
predictors for predicting the MCI subjects’ progression to AD dementia, as summarized in Table S4 and 
S5. The prognostic models built on a combination of demographic data (age, sex, education), cognitive 
measures, and deep learning features had better or similar prediction performance than prognostic 
models built on combinations of demographic data, cognitive measures, and APOE4 statuses or A𝛽 
measures as summarized in tables 1, S6, and S7, indicating that the deep learning imaging features 
could serve as a surrogate if APOE4 or A𝛽 measures are not available.  
Recently studies have also demonstrated promising performance for predicting individual 
subjects’ timing of progression to AD dementia using time-to-event analysis techniques [12-15]. 
Particularly, clinical and imaging based measures at baseline [12, 13, 15] and their longitudinal change 
trajectory [14] have been adopted for predicting MCI subjects’ progression to AD  dementia. In conjunction 
with these studies, our results further demonstrated that the hippocampal MRI data could provide 
informative measures for the prediction of MCI subjects’ timing of progression to AD dementia.  
In the present study, the training imaging data were collected using 1.5T scanners and the testing 
imaging data were collected using 3T scanners. The deep learning features of 1.5 and 3T scans of the 
same ADNI 1 subjects highly correlated with each other and showed high comparability in their predicted 
risk scores, demonstrating that the deep learning features were robust to magnetic field strength 
differences. Therefore, the differences between the training data and testing data in the scanners’ 
magnetic field strength minimally affected the prediction performance. We postulate that the image 
19 
 
intensity normalization used in our study might minimize the difference caused by the scanner’s magnetic 
field strength. 
Our deep learning models could be used to predict AD progression risks for individuals with MRI 
scans collected following the ADNI imaging protocol. The whole pipeline of the proposed prognostic 
model is automatic. It is not sensitive to hippocampus segmentation, as only a bounding box containing 
hippocampus is required. The deep learning feature extraction and prognosis is efficient on both modern 
GPU and CPU (within 1 second) once the trained model is obtained. Particularly, for each subject, it 
takes about 0.011 second on a GPU or about 0.463 second on a CPU to compute deep learning features, 
and it takes 0.1 millisecond to obtain a prognosis result on a CPU. This deep learning tool can be used 
across platforms, including cloud computing, once they are containerized using docker.    
The approach here offers a straightforward and computationally rapid means for a clinician to 
stratify MCI patients about the likelihood of progression within a particular timeframe. This could have 
significant impact on family and patient planning. In light of the fact that prediction accuracy is similar to 
prediction from Aβ measures, this approach may obviate the need for some measures in the clinical 
setting with the advantage of being non-invasive, as opposed to lumbar puncture, and less expensive, 
as compared to amyloid PET. 
 Although the proposed prognostic model has achieved better performance than state-of-the-art 
alternative imaging feature extraction methods for AD prognosis, further efforts are needed in following 
aspects. First, the current study focused on the hippocampus, it is expected to obtain improved prognostic 
performance when the deep learning method is applied to the whole brain MRI data. Second, the current 
study focused on predicting MCI subjects’ progression to AD dementia, but the proposed framework could 
be applied to other clinical endpoints, such as predicting NC subject’s progression to MCI [56] or cognitive 
decline, which could be useful in preclinical AD studies and facilitate subject screening in clinical trial. 
Third, only data at baseline were used in the current study, and we expect that the prognostic 
performance could be boosted if longitudinal data are incorporated into the model. Fourth, the current 
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study focused on the prediction of boundaries between MCI and AD, which may not be well equipped to 
characterize the AD continuum [57].  
The cognitive measures demonstrated better performance than the imaging measures for 
predicting the AD dementia progression as cognition is core component of the diagnosis of dementia, 
which results in circularity of using these measures in this type of prediction. Future work could focus 
more on predicting cognitive change which may be less susceptible to these circularity arguments. 
Additionally, the present study focused on the imaging features and did not fully explored other cognitive 
measures that might be even more informative for the prediction of MCI progression, such as RAVLT 
delayed recall, or impairment in other cognitive domains, such as executive function. Finally, changes in 
activities of daily living are also reflective progression from MCI to dementia and therefore could further 
add prediction. 
Although our method could build time-to-event prediction models with continuous timing 
information, our prediction model largely captured the AD progression on intervals of 6 months because 
the training subjects were followed every 6 months. Since most of the ADNI MCI subjects progressed to 
AD dementia within 36 months, our prediction model might be driven to focus more on the advanced MCI 
subjects and to identify information relevant to late MCI. Moreover, although quantitative results have 
demonstrated that the prognostic model was robust to imaging data collected by scanners with different 
magnetic field strength, other potential confounders regarding subject heterogeneity such as atypical 
forms of AD require further investigation using datasets in clinical settings. One source of comfort related 
to heterogeneity of imaging acquisition for the viability of this approach is that quantitative results have 
demonstrated that the deep learning imaging features were robust to imaging data collected using 
scanners with different magnetic field strengths. It should be noted also that ADNI was designed to mimic 
a clinical trial and that is an additional context, outside of clinical practice, in which the findings here are 
relevant for potentially determining inclusion in an intervention study. Finally, although our study showed 
that the deep hippocampal features have considerable advantages compared to conventional methods 
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such as hippocampal volume, the hippocampus as a structure might be limited in sensitivity and 
specificity for AD prediction and future research should consider further relevant regions. 
In conclusion, the deep learning method for early prognosis of AD dementia could achieve 
promising performance, help distinguish MCI subjects with different progression patterns, and identify 
MCI subjects with higher risk to develop AD dementia, thus providing a cost effective and accurate means 
for prognosis and potentially to facilitate enrollment in clinical trials with individuals likely to progress 
within a specific temporal period. 
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Data  
In the present study, the ADNI-1 scans were collected using 1.5T scanners, the ADNI-GO&2 scans were 
collected using 3T scanners, and the AIBL scans were collected using 3T scanners. The AD diagnosis 
was based on the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) 
and the Alzheimer’s Disease and Related Disorders Association (ADRDA) clinical criteria for probable 
AD. Demographic information of the AD and NC subjects is summarized in Table S1. Compared with the 
ADNI-1 cohort, both the ADNI-GO&2 and the AIBL NC subjects were younger, and the AIBL NC and AD 
subjects had smaller MMSE. 
 
Table S1. Demographic information of the NC and AD subjects included in this study. 
NC and AD subjects 
Cohorts  NC AD 
ADNI-1 
Number of subjects 228 192 
Gender (M/F) 118/110 101/91 
Age 75.97±5.02 75.34±7.45 
MMSE 29.11±1.00 23.31±2.04 
ADNI-GO&2 
Number of subjects 311 158 
Gender (M/F) 142/169 91/67 
Age 72.98±6.09* 74.85±8.09 
MMSE 29.00±1.25 23.1±2.07 
AIBL 
Number of subjects 328 67 
Gender (M/F) 145/183 26/41 
Age 72.30±6.51* 73.28±8.08 
MMSE 28.71±1.21* 20.36±5.67* 
NC: cognitively normal control; AD: Alzheimer’s disease 
*: 𝑝 < 0.05, Wilcoxon rank sum test for Age and MMSE, Chi-Squared test for Gender. 
 
                                                          
*Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database 
(adni.loni.usc.edu) and the Australian Imaging Biomarkers and Lifestyle Study of Aging (AIBL) database (www.aibl.csiro.au). As such, 
the investigators within the ADNI and AIBL contributed to the design and implementation of ADNI and AIBL and/or provided data but did 
not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-
content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf 
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Most of the ADNI MCI subjects were followed every 6 months, and the AIBL MCI subjects were 
followed every 18 months. The follow-up information of the MCI subjects is summarized in Table S2. 
Compared with the ADNI-1 MCI subjects, the ADNI-GO&2 MCI subjects were younger with a different 
gender ratio and had larger MMSE. No significant difference was observed between MCI subjects of the 
ADNI-1 and the AIBL cohorts. 
 
Table S2. Demographic and follow-up information of the MCI subjects included in this study. 
 MCI subjects with follow-up 
Cohorts 
Number of 
subjects 
Gender 
(M/F) 
Age 
(years) 
MMSE 
Follow-up months 
(quartiles) 
Progressors 
Months to progression 
(quartiles) 
ADNI-1 383 246/137 74.73±7.32 27.01±1.77 6-132 ([12, 24, 48]) 208 6-126 ([12, 24, 36]) 
ADNI-
GO&2 
439 242/197* 71.71±7.36* 28.06±1.70* 6-78 ([24, 42, 54) 107 6-60 ([12, 24, 36]) 
AIBL 40 21/19 76.13±7.28 27.25±2.10 18-54 ([18, 36, 54]) 18 18-54 ([18, 18, 36]) 
MCI: mild cognitive impairment; Converter: MCI subjects who progressed to AD dementia before the last 
follow-up visit.  
*: 𝑝 < 0.05, Wilcoxon rank sum test for Age and MMSE, Chi-Squared test for Gender. 
 
Training of the deep classification model (AD versus NC) for imaging feature extraction 
The deep classification model was optimized using stochastic gradient descent algorithm [1], the 
momentum was set to 0.9, and the base learning rate was set to 0.01. The learning rate was updated 
using a stepwise policy, which drops the learning rate by a factor of 0.1 after every 20000 steps. The 
maximum iteration of the training procedure was set to 100000. Batch size of 32 was adopted to update 
weights in the model. The deep learning models were implemented based on Caffe [2], and trained on a 
Nvidia Titan X (Pascal) graphics processing unit (GPU). The classification model was trained using the 
ADNI 1 cohort, and validated using the ADNI-GO&2 cohorts. 
 
 
Fig. S1. Classification performance on the evaluation dataset with different number of train iteration steps. 
To boost the deep learning model’s performance and robustness, data augmentation is adopted 
to generate more training data [3]. Particularly, augmented image data were generated using image 
translation and non-rigid deformable image registration techniques. In particular, each hippocampus 
image along with its corresponding hippocampus masks in the training dataset was translated by 2 voxels 
along 26 directions of 3D image space separately, yielding augmented images that account for translation 
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invariance for training the deep learning model. A non-rigid deformable image registration method, 
namely ANTs [4], was adopted with its default parameter setting to register one hippocampal MRI image, 
referred to as moving image, to another of the same side (left to left and right to right) within the same 
disease category (NC to NC, and AD to AD), and the resulting deformation field was used to deform the 
moving hippocampus image and its hippocampus label to generate deformed hippocampus image and 
label. In total, 10920 spatial translated images, and 44214 non-rigid registered images were generated 
for training the deep learning model. 
To identify the optimal number of training iteration steps, classification performance (area under 
the ROC curve, AUC) of the trained models with different numbers of training iteration steps on the 
evaluation dataset (the ADNI-GO&2) were investigated as shown in Fig. S1, the classification model with 
the highest AUC (with 60000 training iterations) was adopted for imaging feature extraction in this study. 
Fig. S2 shows ROC curves of the binary classifiers for distinguishing AD patients from NC subjects, 
obtained based on the evaluation cohorts using the shape, shape & texture, and deep imaging features 
respectively. The classification accuracy rate obtained by the deep imaging based binary classifier was 
0.900 and 0.929 on the ADNI-GO&2 and AIBL cohorts respectively, while those obtained by the RF 
classifiers built upon hippocampal shape features and a combination of shape and texture features were 
0.829 and 0.866 respectively on the ADNI-GO&2 cohorts, and 0.801 and 0.876 respectively on the AIBL 
cohort. The AUC values obtained by the deep imaging classifier were 0.956 and 0.958 on the ADNI-
GO&2 and AIBL cohorts respectively, while those obtained by the RF classifiers built upon the 
hippocampal shape features and a combination of shape and texture features were 0.886 and 0.913 
respectively on the ADNI-GO&2 cohorts, and 0.853 and 0.883 respectively on the AIBL cohort. Delong 
test indicated that the deep imaging classifier performed significantly better than the RF classifiers in 
terms of their AUC measures (p<0.008). 
 
  
Fig. S2. ROC curves and classification accuracy (Acc) rates obtained by different binary classifiers for distinguishing 
AD patients from NC subjects, including the CNNs based classifier, and RF classifiers built upon the hippocampal 
shape and texture features, on the ADNI-GO&2 (left) and the AIBL cohorts (right).  
 
Comparisons with state-of-the-art imaging features 
We compared the deep learning based imaging features with state-of-the-art feature extraction methods 
for hippocampal MRI images. The feature extraction methods under comparison include conventional 
hippocampal shape and texture features. The conventional hippocampal shape and texture features were 
extracted using a software package (http://pyradiomics.readthedocs.io) [5]. Particularly, the hippocampal 
shape features were extracted from each subject’s left and right hippocampal segmentation labels 
separately, including volume, maximum 3D diameter, maximum 2D diameter (column, row, and slice), 
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surface area, surface volume ratio, flatness, sphericity, elongation, and spherical disproportion. In total, 
22 shape features were extracted for each subject. The hippocampal texture features were extracted 
from the hippocampal images and their counterparts after wavelet decomposition, including the first order 
features, gray level co-occurrence matrix features, gray level size zone matrix features, and gray level 
run length matrix features. In total, 711 textures were extracted from each hippocampus region and 1422 
hippocampal texture features were extracted from each subject.   
 To build the RF classifiers for AD/NC diagnosis, 1000 decision trees were adopted, and the 
minimum leaf size of the tree was set to 5. Sample weight for each training image was set to the ratio 
between total number of training images and the number of images within the same category, and the 
training images were sampled with replacement during the training procedure. The built-in RF 
implementation, namely TreeBagger, in Matlab (R2013a) was adopted to train the RF classifiers, and 
default values were used for other parameters. 
 
Predicted risks of progression to AD dementia for MCI subjects with different amyloid positive 
statuses 
In addition to prognostic accuracy, we compared the predicted AD progression risks between amyloid 
positive and negative MCI subjects of the ADNI-GO&2 cohorts. As illustrated in Fig. S3, MCI subjects 
with A𝛽-negative status had significantly lower progression risks compared with A𝛽-positive subjects, no 
matter whether A𝛽  status was defined based on CSF measure only, PET measure only, or their 
combination (p=3.21 × 10−13, 5.33 × 10−13, 4.14 × 10−14 respectively, Wilcoxon rank sum test).  
Table S3. Amyloid positive and negative MCI subjects of the ADNI-GO&2 cohorts. 
MCI subjects (n=439) 
 CSF A𝛽 (positive) SUVR-1.11 (positive) combination (positive) 
Available subjects 410 (255) 436 (242) 439 (271) 
 
 
CSF 
𝑝 = 3.21 × 10−13 
 
PET 
𝑝 = 5.33 × 10−13 
 
Combination 
𝑝 = 4.14 × 10−14 
Fig. S3. Predicted risks of progression to AD dementia of the ADNI-GO&2 MCI subjects with different amyloid 
positive statuses. The amyloid status was defined based on CSF measure only, PET measure only, and their 
combination. 
 
When imaging features meet clinical variables for prognosis 
Beyond the AD progression risks estimated based on the deep learning imaging features, we have also 
built a second prognostic model of MCI subjects based on a combination of AD classification scores 
(probabilities) estimated by the deep learning AD/NC classification model and baseline clinical measures 
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as described previously using Cox regression [6]. The prognostic model was also trained on the ADNI-1 
cohort and evaluated on the ADNI-GO&2 cohorts. Details of the obtained Cox regression model are 
demonstrated in Table S4. The model obtained similar performance as that obtained by the AD 
progression risk based prognostic model, with a C-index 0.861. The AD classification score was 
significantly associated with the prognosis as demonstrated in Table S4, indicating that it could provide 
complimentary information when combined with clinical measures for the prognosis.  
 
Table S4. Cox regression model of progression to AD dementia of MCI subjects, built on a combination of AD 
classification score estimated by the deep learning AD/NC classification model and baseline clinical measures. 
Variables coef Hazard ratio: Exp(coef) Se(coef) z p 
Age -0.071 0.931 0.077 -0.93 0.354 
Sex 0.144 1.155 0.078 1.86 0.063 
Education 0.109 1.116 0.073 1.49 0.135 
APOE4 0.166 1.180 0.075 2.22 0.026 
ADAS-Cog13 0.206 1.229 0.104 1.98 0.048 
RAVLT_immediate -0.495 0.610 0.109 -4.54 5.6e-06 
RAVLT_learning 0.095 1.100 0.092 1.03 0.301 
FAQ 0.340 1.404 0.060 5.69 1.3e-08 
MMSE -0.102 0.903 0.080 -1.28 0.200 
Deep learning imaging feature 
based AD score 
0.405 1.499 0.090 4.51 6.4e-06 
Likelihood ratio test=177.6  on 10 df, p<2e-16, n=383, number of events=208 
ADAS-Cog13: the 13-item version of the Alzheimer’s Disease Assessment Scale-Cognitive subscale; RAVLT: Rey 
Auditory Verbal Learning Test; FAQ: Functional Assessment Questionnaire; MMSE: Mini-Mental State Examination. 
 
Table S5 summarizes the Cox regression model of progression to AD of MCI subjects built on 
baseline clinical variables and the prognostic risk of progression to AD dementia derived from the deep 
learning imaging features. Since the prognostic risk of progression to AD dementia derived from the deep 
learning imaging features were derived based on the ADNI-1 MCI subjects, its p-value was subject to a 
circular analysis risk. Therefore, we evaluated the deep leaning based imaging features based on the AD 
classification scores which were derived from the AD and NC subjects, independent on the MCI subjects, 
as summarized in Table S4. 
 
Table S5. Cox regression model of conversion to AD of MCI subjects when combining deep imaging feature based 
risk of conversion to AD dementia and baseline clinical variables. 
Variables coef Hazard ratio: Exp(coef) Se(coef) z p 
Age -0.1615 0.8509 0.0803 -2.01 0.044 
Sex 0.1266 1.1350 0.0771 1.64 0.101 
Education 0.0668 1.0691 0.0740 0.90 0.367 
APOE4 0.1334 1.1427 0.0743 1.80 0.073 
ADAS-Cog13 0.1567 1.1696 0.1040 1.51 0.132 
RAVLT_immediate -0.5067 0.6025 0.1098 -4.61 3.9e-06 
RAVLT_learning 0.0895 1.0937 0.0907 0.99 0.324 
FAQ 0.3358 1.3990 0.0610 5.51 3.6e-08 
MMSE -0.0737 0.9290 0.0812 -0.91 0.364 
Deep learning imaging feature 
based the prognostic risk 
0.5430 1.7211 0.0894 6.07 1.3e-09 
Likelihood ratio test=192.1  on 10 df, p=<2e-16, n= 383, number of events= 208 
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As shown in Fig. S4, the prediction model built on a combination of the deep learning imaging 
features and clinical measures obtained time-dependent AUC measures of 0.885, 0.892, and 0.916 at 
follow-up durations from year 1 to year 3 respectively, better than the prediction model built upon the 
clinical measures alone (p=0.466, 0.054, and 0.067 at years 1 to 3 respectively). 
 
Fig. S4. Time-dependent ROC curves of prognostic models built upon baseline clinical measures and combination 
of clinical measures and the prognostic risk of conversion to AD derived from deep learning features at follow-up 
durations from year 1 to year 3 on the ADNI-GO&2 cohorts. 
We have further evaluated prediction models built on different combinations of imaging features, 
CSF A𝛽 measures, APOE4 status, cognitive measures, and demographic data (age, sex, and education), 
in addition to the evaluation of prediction models built on imaging features, clinical measures (APOE4 
status, all cognitive measures, and demographic data), and their combination. All the prediction models 
were built on the ADNI-1 cohort and evaluated based on the ANDI-GO&2 cohorts and the AIBL cohort. 
We have not evaluated the prediction models built on the clinical measures or CSF A𝛽 measures on the 
AIBL data set because the AIBL cohort and the ADNI cohorts had different clinical measures and we do 
not have access to the AIBL CSF A𝛽 measures. 
For A𝛽 measures, we focused on CSF measures for its wide availability in the ADNI 1, 2, and GO 
cohorts. Since CSF A𝛽 measures were not available for a proportion of the MCI subjects (6.6%), we had 
two different pairs of training/testing data sets. One pair of the training/testing data sets consist of subjects 
with imaging features and clinical measures including APOE4 status, cognitive measures, and 
demographic data (CSF A𝛽 measure was not considered). This pair of data sets were used to obtain 
results summarized in Table 1 and Table S6. The other pair of the training/testing data sets consist of 
subjects with all imaging features, clinical measures aforementioned, and CSF A𝛽 measure (subjects 
without CSF A𝛽 measures were excluded). Prediction performance measures obtained based on this 
pair of data sets are summarized in Table S7.  
Table S6 summarizes performance measures of prediction models built on imaging features, 
APOE4 status, cognitive measures, demographic data, and their combinations (without taking into 
consideration A𝛽 measures). The demographic measures were included in all the prediction models. 
Each element of Table S6 shows C-index values obtained by a prediction model built on measures shown 
in its corresponding row and column. Particularly, the combination of the deep learning imaging features 
and demographic measures had significantly better prediction performance than the combination of 
MMSE and demographic measures (p=0.0004). Among the cognitive measures, ADAS-cog 13 had the 
best prediction performance when combined with demographic measures, and the difference in terms of 
prediction performance between the deep learning imaging features and the ADAS-Cog13 was not 
statistically significant when combined with the demographic data (p=0.257).  
The combination of cognitive measures had the overall best prediction performance. This result 
is not surprising as cognition is core component of the diagnosis of dementia, and therefore the prediction 
performance of cognitive measures for progression to dementia likely reflect some circularity. 
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Table S6. Prediction performance of models built on different combinations of demographic data, cognitive 
measures, APOE4, and different types of imaging features. 
C-index Demographic +ADAS13 
+RAVLT 
immediate 
+RAVLT 
learning 
+FAQ +MMSE 
+all cognitive 
measures 
Demographic 0.478 0.789 0.754 0.665 0.770 0.644 0.842 
+APOE4 0.652 0.801 0.778 0.710 0.778 0.703 0.848 
+Shape 0.665 0.803 0.783 0.715 0.779 0.707 0.847 
+Shape & Texture 0.699 0.808 0.797 0.729 0.789 0.736 0.852 
+Deep Image risk (DIR) 0.763 0.818 0.825 0.772 0.811 0.779 0.858 
+DIR & APOE4 0.777 0.825 0.832 0.786 0.824 0.792 0.864 
 
Table S7 summarizes performance measures of the prediction models built on imaging features, 
CSF A𝛽 measures, APOE4 status, cognitive measures, demographic measures, and their combinations. 
Both A𝛽 status (positive or negative) and A𝛽 value were evaluated. Similarly, the demographic measures 
were included in all the prediction models, and each element of Table S7 shows C-index values obtained 
by a prediction model built on measures shown in its corresponding row and column. Particularly, the 
deep learning imaging features had better performance than the CSF A𝛽 measures (status or value) and 
APOE4 status (the first column of Table S7) when combined with the demographic data. However, they 
had similar prediction performance if they were combined with all cognitive measures (the last column of 
Table S7), indicating that the deep learning imaging features might serve as a surrogate for these 
measures. Furthermore, prediction models built on individual cognitive measures did not obtain 
significantly better prediction performance than the prediction model built on the deep learning imaging 
features when combined with the demographic data.  
 
Table S7. Prediction performance of models built on different combinations of demographic data, cognitive 
measures, APOE4, CSF A𝛽 measures (status: positive/negative, or continuous measure) and different types of 
imaging features. (p values between prognostic models based on demographic data & deep image risk and 
demographic data & single alternative clinical measure or combination of APOE4 and A𝛽 measure are demonstrated 
in the parenthesis). 
C-index Demographic +ADAS13 
+RAVLT 
immediate 
+RAVLT 
learning 
+FAQ +MMSE 
+all cognitive 
measures 
Demographic 0.516 
0.779 
(0.425) 
0.741 
(0.518) 
0.663 
(0.0009) 
0.762 
(0.962) 
0.649 
(0.0006) 
0.819 
+APOE4 0.644 (0.0002) 0.791 0.761 0.695 0.779 0.691 0.827 
+A𝛽 status 0.668 (0.008) 0.804 0.780 0.735 0.793 0.734 0.836 
+ A𝛽 value 0.701 (0.03) 0.801 0.775 0.727 0.789 0.735 0.831 
+ A𝛽 status & APOE4 0.683 (0.004) 0.805 0.783 0.738 0.798 0.737 0.838 
+ A𝛽 value & APOE4 0.706 (0.045) 0.802 0.778 0.727 0.791 0.736 0.833 
+Shape 0.673 (0.0008) 0.795 0.777 0.717 0.780 0.712 0.824 
+Shape & Texture 0.690 (0.002) 0.796 0.781 0.725 0.779 0.729 0.828 
+Deep Image risk (DIR) 0.759 0.805 0.809 0.767 0.809 0.773 0.840 
+DIR & A𝛽 status  0.796 0.822 0.823 0.794 0.835 0.800 0.852 
+DIR & A𝛽 value 0.788 0.820 0.821 0.791 0.831 0.799 0.849 
+DIR & A𝛽 status & APOE4   0.796 0.822 0.824 0.795 0.834 0.802 0.851 
+DIR & A𝛽 value & APOE4   0.793 0.819 0.821 0.791 0.831 0.799 0.849 
 
Fig. S5 shows time-dependent AUC measures of the AIBL MCI subjects at year 2 and year 3 
obtained by prediction models built on the deep learning imaging features, shape features, and a 
combination of shape and texture features (follow-up information at 12 months is not available). The time-
dependent AUC measures indicated that the deep learning features had better prediction performance 
than the conventional shape and texture imaging features. Fig. S6 shows Kaplan-Meier plots of MCI 
subgroups with different progression risks in terms of progression to AD estimated by the deep learning 
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prediction model on the AIBL cohort. Statistically significant group difference was observed in terms of 
their progression time to AD dementia (Log-rank test, p<0.009). 
 
 
Fig. S5. Time-dependent ROC curves of prognostic models built upon different imaging features at follow-up 
durations from year 2 to year 3 on the AIBL cohort (clinical outcomes at year 1 is not available in AIBL cohort). The 
prediction model built on the deep learning features was significantly better than the prediction model built on the 
shape features in terms of their time dependent AUC values at both year 2 and year 3 with p values of 0.011 and 
0.055 respectively. The difference in AUC values was not statistically significant between prediction models built on 
the deep learning features and the shape and texture features with p values of 0.122 and 0.08 at year 2 and year 
3, respectively.   
 
Fig. S6. Kaplan-Meier plot of MCI subgroups with different progression risks in terms of progression to AD dementia 
estimated by the deep learning prediction model on the AIBL cohort (Low: smaller than the median, High: equal or 
larger than the median). The subgroups were significantly different in their conversion timing to AD (Log-rank test, 
p<0.009). 
As summarized in Table S1 and Table S2, significant differences were observed between the 
training data (the ADNI-1 cohort) and the testing data (the ADNI-GO&2 and the AIBL cohorts) in their 
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age, MMSE, and gender ratios. The differences between MCI subjects the ADNI-1 and the ADNI-GO&2 
cohorts are probably caused by the inclusion of an early MCI (EMCI) category in the ADNI-GO&2 cohorts. 
We evaluated the deep learning classification performance based on subsets of the ADNI-GO&2 and 
AIBL cohorts with matched baseline characteristics with the ADNI-1 cohort. Particularly, younger NC 
subjects of the ADNI-GO&2 and the AIBL cohorts and AIBL NC and AD subjects had smaller MMSE 
were excluded in this evaluation. The resulting demographic information of the subsets of the ADNI-
GO&2 and the AIBL cohorts is summarized in Table S8.  
As shown in Fig. S7, the deep learning classifier had better performance than the RF classifiers 
built on the hippocampal shape features and a combination of shape and texture features on both the 
ADNI-GO&2 and AIBL cohorts. However, the overall classification accuracy and AUC measures were 
smaller than those estimated based on all available NC and AD subjects of the ADNI-GO&2 and AIBL 
cohorts.  
 
Table S8. Demographic information of the NC and AD subjects in subsets of the ADNI-GO&2 and the AIBL cohorts 
with matched age, gender, and MMSE measures with the ADNI-1 cohort. 
NC and AD subjects 
Cohorts  NC AD 
ADNI-1 
Number of subjects 228 192 
Gender (M/F) 118/110 101/91 
Age 75.97±5.02 75.34±7.45 
MMSE 29.11±1.00 23.31±2.04 
ADNI-GO&2 
Number of subjects 225 158 
Gender (M/F) 106/119 91/67 
Age 75.27±4.90 74.85±8.09 
MMSE 29.00±1.31 23.1±2.07 
AIBL 
Number of subjects 178 55 
Gender (M/F) 83/95 22/33 
Age 75.25±4.58 73.31±7.92 
MMSE 29.07±0.82 22.49±3.21 
NC: cognitively normal control; AD: Alzheimer’s disease 
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Fig. S7. ROC curves and classification accuracy (Acc) rates obtained by different binary classifiers for distinguishing 
AD patients from NC subjects, including the deep learning classifier, and RF classifiers built upon the hippocampal 
shape and texture features, estimated based on subsets of the ADNI-GO&2 (left) and AIBL (right) cohorts with 
matched age, gender, and MMSE measures.  
 
We further evaluated the deep learning prognostic model based on a subset of the ADNI-GO&2 
MCI subjects with matched baseline characteristics with the ADNI-1 MCI subjects.  Particularly, younger 
MCI subjects with larger MMSE of the ADNI-GO&2 cohorts were excluded in this evaluation. The resulting 
demographic information of the MCI subset of the ADNI-GO&2 cohorts is summarized in Table S9.  
As summarized in Table S10, the prediction model built on the deep learning imaging features 
had better performance than those build on the conventional shape features and a combination of shape 
and texture features, and the prediction model built on a combination of deep learning features and 
clinical measures had better performance than the prediction model built on the clinical measures alone. 
However, the C-index values were smaller than those estimated based on all available MCI subjects of 
the ADNI-GO&2 cohorts.  
In summary, the results shown in Fig. S7 and Table S10 indicated that prediction performance 
could not be improved by simply removing testing data points to obtain a testing data set matched with 
the training data set in terms of simple characteristics, such as age and MMSE, indicating that more 
sophisticated data harmonization techniques are needed and merit further investigation.   
 
 
Table S9 Demographic and follow-up information of the MCI subset of the ADNI-GO&2 cohorts with matched age, 
gender, and MMSE measures with the ADNI-1 MCI subjects. 
 MCI subjects with follow-up 
Cohorts 
Number of 
subjects 
Gender 
(M/F) 
Age 
(years) 
MMSE 
Follow-up months 
(quartiles) 
Progressors 
Months to progression 
(quartiles) 
ADNI-1 383 246/137 74.73±7.32 27.01±1.77 6-132 ([12, 24, 48]) 208 6-126 ([12, 24, 36]) 
ADNI-
GO&2 
211 125/86 73.87±6.49 26.72±1.34 6-78 ([24, 36, 48) 107 6-60 ([12, 24, 36]) 
MCI: mild cognitive impairment; Converter: MCI subjects who progressed to AD dementia before the 
last follow-up visit.  
 
 
Table S10. Prediction performance of prognostic models built upon different types of features, estimated based the 
MCI subset of the ADNI-GO&2 cohorts with matched age, gender, and MMSE measures with the ADNI-1 MCI 
subjects. 
            C-index 
 
Cohort 
Hippocampal imaging features Clinical 
measures 
Clinical measures with deep 
learning imaging features 
Shape Shape & Texture Deep learning 
ADNI-GO&2 0.646  0.673  0.731 0.833  0.842 
The clinical measures included APOE4 status, all cognitive measures, and demographic data. 
 
We have found that 13 (ADNI 1), 32 (ADNI GO&2), and 3 (AIBL) MCI subjects at baseline have 
reverted to cognitively normal state at their last visit. Therefore, we also evaluated the prognosis models 
by excluding these subjects. Particularly, we trained and evaluated the prognosis models with these 
subjects excluded using the same training and evaluation procedure as described in the manuscript. The 
prognosis performance is summarized in Table S11. The C-index values are similar to those reported in 
the manuscript. The deep learning based features are more discriminative than the conventional shape 
and texture features, and could provide complimentary information to clinical measures for prediction. It 
is noteworthy that the inclusion of MCI subjects with reversion did not violate the assumption of the 
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prognosis model, as they are likely to have lower risk of progression to AD compared to subjects with 
stable MCI. 
 
Table S11. Prediction performance of prognostic models built upon different types of features after excluding MCI 
subjects who converted to cognitively normal state at the last visit. 
            C-index 
 
Cohort 
Hippocampal imaging features Clinical 
measures 
Clinical 
measures with 
deep imaging 
features Shape Texture Deep learning 
ADNI GO&2 0.657 0.686 0.746 0.837 0.852 
AIBL 0.648 0.750 0.822   
 
When volume measures of hippocampus are used for prognosis 
Other than shape based features used in this study, we have also built a prognostic model based on only 
volume measures of left and right hippocampus using Cox regression for predicting MCI subjects’ 
progression to AD dementia. The volume based model predicted the ADNI-GO&2 MCI subjects’ 
progression to AD dementia with a C-index of 0.651 (A𝛽-positive subjects’ progression to AD with a C-
index of 0.631), and the AIBL MCI subjects’ progression to AD dementia with a C-index of 0.691, 
comparable to prediction model built up shape features (p=0.239 and 0.344 [7] on the ADNI-GO&2 and 
the AIBL cohorts respectively) and worse than prediction models built on texture imaging features 
(p=0.018 and 0.104 on the ADNI-GO&2 and the AIBL cohorts respectively) and deep learning imaging 
features (p=0.0005 and 0.124 on the ADNI-GO&2 and the AIBL cohorts respectively). These results also 
demonstrated that advanced imaging features were more informative for the prognosis. 
Concordance index (C-index) used for evaluating the prognostic performance 
The C-index is a generalization of the area under the ROC curve (AUC) for validating the predictive ability 
of a time-to-event analysis model. The C-index was estimated as 𝐶𝑖 =
1
|𝑃|
∑ 𝐼(ℎ𝑟(𝑥𝑖) < ℎ𝑟(𝑥𝑗))(𝑖,𝑗)∈𝑃 , 
where 𝑃 is the set of all orderable pairs of subjects, |𝑃|  is the number of pairs in 𝑃,  ℎ𝑟(𝑥) is a predicted 
risk of a subject with features of 𝑥, and 𝐼  is an indicator function of whether a condition is satisfied or not. 
Larger C-index indicates better prediction. In the present study, an orderable pair of MCI subjects must 
have at least one MCI converter. Two MCI subjects who did not progress to AD dementia are not 
orderable since we do not know which one will progress to AD dementia earlier than the other one. For 
the MCI subjects of the ADNI-GO&2 cohorts, we have 33739 orderable pairs. The difference of 0.02 
between C-index values of two prediction models indicates that the model with a larger C-index value 
correctly predicted ~675 pairs more than the model with a smaller C-index value.  
 
Implementation and feasibility of transferring to other settings 
The whole pipeline of the proposed prognostic model is automatic. Our method is not sensitive to 
hippocampus segmentation, as only a bounding box containing hippocampus is defined based on the 
segmentation result. The deep learning feature extraction and prognosis is efficient on both GPU and 
CPU (within 1 s) once the trained model is obtained. Particularly, for each subject, it takes ~20 mins on 
a standard PC to segment the hippocampus, it takes ~0.011 s on a GPU or ~0.463 s on a CPU to compute 
deep learning features, and it takes ~0.1ms to obtain a prognosis result on a CPU.  
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Source codes and scripts of the hippocampus segmentation method used in the present study are 
available at www.nitrc.org/frs/?group_id=1242. Comparison results with alternative hippocampus 
segmentation methods are available at https://doi.org/10.3389/fninf.2018.00069.  
The deep learning codes can be used across platforms, including cloud computing, once they are 
containerized using docker (www.docker.com).  
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